Patients with IDH2-mutated AML had a higher CR/CRi rate with STANDARD than with azacitidine-containing regimens (8/16 [50%] and 1/16 [6%], p = 0.02, respectively); similarly, CR/CRi rate in patients with RUNX1-mutated AML was in trend superior in STANDARD (10/15, 66%) compared to azacitidine-regimens (11/31 35%, p = 0.06). Here, IDH2 is linked to acute myeloid leukemia.